Daniel Gruener

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

Eric Lawitz, Daniel Gruener, John M. Hill et al. · Journal of Hepatology · 2012 · 158 citations

Hepatology, Hepatitis C, Medicine +8

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 108 citations

Neurodegenerative Diseases, Neuropsychology, Alzheimer's Disease +11

Cognitive Therapy with Chronic Pain Patients

Carrie Winterowd, Aaron T. Beck, Daniel Gruener · Pain Practice · 2004 · 80 citations

Pain Therapy, Pain Syndrome, Health Sciences +11

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine

Lynn R. Webster, Daniel Gruener, Todd Kirby et al. · Pain Medicine · 2016 · 32 citations · Full text

Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C

Eric Lawitz, Daniel Gruener, Thomas Marbury et al. · Antiviral Therapy · 2014 · 30 citations